Marshall Wace, LLP Biogen Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Biogen Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 66,300 shares of BIIB stock, worth $10.4 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

66,300

Holding current value

$10.4 Million

% of portfolio

0.02%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$189.07 - $236.8 $12.5 Million - $15.7 Million	66,300 New	66,300 $12.9 Million
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $4.92 Million - $6.22 Million	23,228 New	23,228 $5.01 Million
Q2 2023 Aug 14, 2023	SELL	$275.25 - $318.06 $145 Million - $168 Million	-527,878 Reduced 99.05%	5,055 $1.44 Million
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $182 Million - $208 Million	-711,217 Reduced 57.16%	532,933 $148 Million
Q4 2022 Feb 14, 2023	BUY	$252.44 - $306.72 $276 Million - $335 Million	1,093,576 Added 726.27%	1,244,150 $345 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $13 Million - $18 Million	66,866 Added 79.88%	150,574 $40.2 Million
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $6.48 Million - $7.71 Million	-34,551 Reduced 29.22%	83,708 $17.1 Million
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $17.6 Million - $22.2 Million	90,805 Added 330.75%	118,259 $24.9 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $3.59 Million - $4.61 Million	16,032 Added 140.36%	27,454 $6.59 Million
Q3 2021 Nov 15, 2021	SELL	$282.99 - $369.05 $181 Million - $236 Million	-639,898 Reduced 98.25%	11,422 $3.23 Million
Q2 2021 Aug 13, 2021	BUY	$259.0 - $414.71 $127 Million - $203 Million	488,764 Added 300.67%	651,320 $226 Million
Q1 2021 May 17, 2021	SELL	$242.95 - $284.63 $86.8 Million - $102 Million	-357,297 Reduced 68.73%	162,556 $45.5 Million
Q4 2020 Feb 16, 2021	BUY	$236.26 - $355.63 $95.3 Million - $143 Million	403,268 Added 345.9%	519,853 $127 Million
Q3 2020 Nov 16, 2020	BUY	$264.77 - $305.71 $18.3 Million - $21.2 Million	69,220 Added 146.14%	116,585 $33.1 Million
Q2 2020 Aug 13, 2020	SELL	$258.66 - $342.55 $4.39 Million - $5.82 Million	-16,987 Reduced 26.4%	47,365 $12.7 Million
Q1 2020 May 15, 2020	BUY	$268.85 - $341.04 $1.24 Million - $1.58 Million	4,630 Added 7.75%	64,352 $20.4 Million
Q4 2019 Feb 14, 2020	BUY	$220.06 - $304.07 $10.5 Million - $14.5 Million	47,816 Added 401.61%	59,722 $17.7 Million
Q1 2019 May 14, 2019	BUY	$216.71 - $338.96 $105,104 - $164,395	485 Added 4.25%	11,906 $2.81 Million
Q4 2018 Feb 14, 2019	SELL	$278.5 - $352.75 $198,849 - $251,863	-714 Reduced 5.88%	11,421 $3.44 Million
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $3.56 Million - $4.66 Million	12,135 New	12,135 $4.29 Million
Q1 2018 May 15, 2018	SELL	$260.13 - $367.91 $5.3 Million - $7.49 Million	-20,356 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $3.68 Million - $4.12 Million	11,946 Added 142.05%	20,356 $6.49 Million
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $2.36 Million - $2.77 Million	8,410	8,410 $2.63 Million

Others Institutions Holding BIIB

# of Institutions

1,038

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $22.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Biogen Inc. Transaction History